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Perspective

Mesenchymal Stem cells derived from human perinatal
tissues as a model for drug screening and toxicity testing
– A perspective
Nitya Shree* and Ramesh R Bhonde
Backgroud
Stem cells have a great potential for basic research
and hold the future for clinical applications. These
cells have characteristic features quite unique from
other cells i.e., they are capable of self-renewal and
differentiating into any cell type. The two types of
stem cells being considerably worked on are the
embryonic stem cells (ESCs) and the adult stem
cells1.
ESCs are pluripotent cells and hence capable of
differentiating into all three germ layers viz.,
endoderm, mesoderm, and ectoderm2. Adult stem
cells are generally regarded as multipotent having
the capability of differentiating into limited cell
types. However, some reports show evidence of
having pluripotent nature in adult stem cells like
mesenchymal stem cells (MSCs) 3, though it is not
generally accepted. In general, MSCs are capable of
differentiating into adipocytes, chondrocytes, and
osteocytes4.
MSCs vary significantly in their paracrine secretions
based on the tissue of origin5,6. This difference is
probably required for the maintenance of the tissue
homeostasis in which they are residing. All the
MSCs have immune regulatory properties7. Area
of mesenchymal stem cells (MSCs) has flourished
lately. Mesenchymal stem cells can be isolated from
Nitya Shree

School of Regenerative Medicine, GKVK Post, Bellary Road,
Allalsandra, Bangalore-560065. Email: nitya.sip@gmail.com

Ramesh R Bhonde

School of Regenerative Medicine, GKVK Post, Bellary Road,
Allalsandra, Bangalore-560065. Email: rr.bhonde@manipal.edu
* Corresponding Author

perinatal and postnatal tissues. MSCs are present in
almost all the postnatal organs viz., liver, skeletal
muscle, adipose tissue, heart, lung, brain etc. making
their presence ubiquitous. However, it is not possible
to recover these MSCs for research purposes as it
evokes ethical issues and technical difficulties. Hence,
the best choice left to researchers is perinatal tissue
available as biological waste. Perinatal MSCs can
be harvested from various sources viz., cord blood,
umbilical cord, placenta, amnion, and chorion8.
These MSCs are the promising resources for
autologous stem cell transplantation because they
are the biological wastes that are easily available with
negligible legal issues. The most important features
of these MSCs are that they are human origin and
represent normal diploid cell population having
finite life. Human diploid cells have been employed
in viral vaccine preparation such as rabies. It is very
difficult to prepare and establish human diploid cell
culture such as MRC5 and MRC9 derived from
human fetal lung and kidney respectively. Under
this scenario, human tissue derived MSCs come to
our rescue to form a novel alternative/ substitute for
drug screening 9. A study performed by Petlzer et al.,
highlighted the importance of elaborated predictive
in vitro test to screen between-donor variability of
perinatal tissues for banking allogeneic standardized
MSCs. Perinatal MSCs are useful for ex vivo
expansion of hematopoietic progenitor cells as they
have the potential to modulate the in vitro immune
response 10. Umbilical cord MSCs and placentaderived MSCs are considered to be genetically stable
under hostile in vivo situations, demonstrating their
suitability to be used for therapy 11.
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The screening of genotoxic compounds are done
by a widely known micronucleus test. To reduce the
number of animal experiments carried out; high
throughput screening of compounds can use MSCs
as a substitute to peripheral lymphocytes and cancer
cell lines 12.
Pharmacological investigations include screening
the compounds on both in vitro and in vivo models.
In vivo models involve a lot of animals and ethical
clearances. In vitro model on the other hand
comprise the primary cell culture, established cell
lines, organ culture, embryo culture and threedimensional cultures for specialized cells. All have
their own advantages and disadvantages. The most
widely used ones are the established cell line, which
are either primate or non-primate origin. If it is a
primate cell line i.e., a human cell line, it is mostly
the cancer cell line. If one has to study an in vitro
phenotypic instability of hepatocytes, there are some
limitations in harvesting liver cells from human,
which raises an ethical concern, non-availability of
the fresh liver from humans for harvesting cells and
hepatocyte preparation from different donors will
have high batch to batch variation in the assessment
of drug toxicity.
To overcome the above limitations, different models
using the cell lines derived from human have been
proposed for screening; one of the classic examples
being HepG2 (human hepatoma cell line), they show
minimal levels of drug metabolizing action and do
not establish a real alternative to primary hepatocytes.
Pharmaceutical companies progressively make use
of cell lines to speed up the selection of new drugs
with promising pharmacokinetic and metabolic
properties 13. Cell lines serve as the most feasible
alternative even though they tend to exhibit
problems in stability 14. The development of cell line
based model that exactly mimics the human in vivo
conditions is lacking and there are various factors,
which need to be looked at before selecting a cell line
for screening. None of the models discussed above
depicts the actual human physiological conditions.
Therefore, stem cell based model is the best option.
Stem cells may also be a source for the generation
of various cell types in vitro. Such In vitro models
have an advantage of being used as an alternative to
34
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animals and the application includes transplantation,
tissue engineering and in drug and vaccines research.
Based on the previous reports, it is established that
MSCs especially from perinatal tissues and their
differentiated progeny can be used as a model for
screening drugs and toxicity assays. The employment
of perinatal tissue derived MSCs prove the concept
of “Trash to Treasure” and provide suitable
substitute for animal experimentation serving three
“R” principle of Replacement, Refinement, and
Reduction in animals. In the modern era of stem
cells, MSCs and their differentiated progeny, such as
islets, hepatocytes, cardiomyocytes etc. can be used
as a novel means for screening drugs for cell specific
disease thereby minimizing the cost of procuring the
specific cell lines and using that for the experiment
as depicted in Figure 1:

Figure 1: Stem cells and their progeny as In vitro model
for drug testing
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